Status:

COMPLETED

Navitian PMCF Study ( rEPIC04C )

Lead Sponsor:

Fundación EPIC

Conditions:

Coronary Artery Disease (CAD)

Ischemic Heart Disease

Eligibility:

All Genders

18+ years

Brief Summary

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Navitian to meet EU Medical Device regulation (MDR) ...

Detailed Description

The objective of this multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study is to confirm and support the clinical safety and performance of the Navitian in a NON-SELEC...

Eligibility Criteria

Inclusion

  • Patient treated with Navitian according to routine hospital practice and following instructions for use
  • Informed consent signed

Exclusion

  • Not meet inclusion criteria

Key Trial Info

Start Date :

September 26 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 11 2024

Estimated Enrollment :

102 Patients enrolled

Trial Details

Trial ID

NCT05292118

Start Date

September 26 2022

End Date

July 11 2024

Last Update

March 5 2025

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Centro Hospitalar Vila Nova de Gaia

Vila Nova de Gaia, Portugal, 4434-502

2

Hospital Universitari Vall D'Hebron

Barcelona, Spain, 08035

3

Hospital Clinic de Barcelona

Barcelona, Spain, 08036

4

Hospital Universitario Juan Ramon Jimenez

Huelva, Spain, 21005

Navitian PMCF Study ( rEPIC04C ) | DecenTrialz